Debio 0932

• Description :

  Debio 0932 (CUDC-305) is an orally active HSP90 inhibitor, with IC50s of 100 and 103 nM for HSP90α and HSP90β, respectively[1].

• Product Name Alternative :

  CUDC-305

• UNSPSC :

  12352005

• Target :

  HSP

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Debio-0932.html

• Purity :

  99.97

• Solubility :

  DMSO : 75 mg/mL (ultrasonic)

• Smiles :

  NC1=NC=CC2=C1N=C(SC3=C(N(C)C)C=C(OCO4)C4=C3)N2CCNCC(C)(C)C

• Molecular Formula :

  C22H30N6O2S

• Molecular Weight :

  442.58

• References & Citations :

  [1]Bao R, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 2009 Jun 15;15 (12) :4046-57.|[2]Stenderup K, et al. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol. 2014 Nov;94 (6) :672-6.|[3]Bao R, et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 2009 Dec;8 (12) :3296-306.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  HSP90

• CAS Number :

  [1061318-81-7]